KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Payables: 2017-2024

Historic Payables for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $735.5 million.

  • Amneal Pharmaceuticals' Payables rose 9.05% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 11.99%. This contributed to the annual value of $735.5 million for FY2024, which is 27.66% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' Payables stood at $735.5 million, which was up 27.66% from $576.1 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Payables peaked at $735.5 million during FY2024, and registered a low of $525.3 million during FY2021.
  • Its 3-year average for Payables is $629.8 million, with a median of $577.9 million in 2022.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Payables dropped by 14.28% in 2021, and later rose by 27.66% in 2024.
  • Amneal Pharmaceuticals' Payables (Yearly) stood at $612.9 million in 2020, then dropped by 14.28% to $525.3 million in 2021, then increased by 10.00% to $577.9 million in 2022, then declined by 0.31% to $576.1 million in 2023, then rose by 27.66% to $735.5 million in 2024.